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Hematopoiesis entails a series of hierarchically organized events that proceed throughout cell speciﬁcation and terminates with
cell differentiation. Commitment needs the transcription factors’ effort, which, in concert with microRNAs, drives cell fate and
responds to promiscuous patterns of gene expression by turning on lineage-speciﬁc genes and repressing alternate lineage
transcripts. We obtained microRNA proﬁles from human CD34þ hematopoietic progenitor cells and in vitro differentiated
erythroblasts, megakaryoblasts, monoblasts and myeloblast precursors that we analyzed together with their gene expression
proﬁles. The integrated analysis of microRNA–mRNA expression levels highlighted an inverse correlation between microRNAs
speciﬁcally upregulated inone single-cell progeny and their putative target genes, which resulted in downregulation. Among the
upregulated lineage-enriched microRNAs, hsa-miR-299-5p emerged as having a role in controlling CD34þ progenitor fate,
grown in multilineage culture conditions. Gain- and loss-of-function experiments revealed that hsa-miR-299-5p participates in
the regulation of hematopoietic progenitor fate, modulating megakaryocytic-granulocytic versus erythroid-monocytic
differentiation.
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Cell fate decisions in the hematopoietic system appear to
be directed by an antagonistic or synergistic interplay of
transcription factors that pivot immature blood progenitors for
cell speciﬁcation.
1 Multipotent progenitors initially trigger a
promiscuous transcriptional program,
2,3 and as soon as they
commit to a restricted fate, they reinforce unilineage gene
expression and withdraw transcripts afﬁliated with alternative
blood cell types.
4,5 MicroRNAs appear to be especially
pertinent in driving this particular behavior representing
a new component of the hematopoietic gene regulatory
network.
6 In fact, the archetypal microRNA can potentially
regulate hundreds of genes
7–10 even if most targets contain
isolated microRNA recognition sites that may be inadequate
for complete gene silencing. According to Bartel’s theory,
11
microRNA-mediated post-transcriptional control offers a
more ﬂexible and rapid way of tuning genes compared with
transcriptional control. These issues encouraged some
investigators to explore the association of microRNAs and
genes expression proﬁles obtained from the same cell
type,
7,12–14 and advocated that microRNAs evolved to regu-
late gene expression programs and remove gene products
unnecessary orpotentially dangerousmorerapidly thanmight
occur by natural decay. So far, these conclusions have not
been fully substantiated in physiological myelopoiesis.
Although many studies addressed the role of microRNAs
during the normal myeloid differentiation process,
15–20 only
Georgantas et al.
21 focused on the impact of microRNAs on
mRNA expression levels but limited the analyses to data
obtained from human CD34þ stem/progenitor cells.
21 To
shed light on the interplay of mRNAs and microRNAs during
the normal myeloid commitment and verify that increased
expression of a microRNA is skillful in modulating the levels of
corresponding target mRNAs, we obtained microRNA
proﬁles from CD34þ hematopoietic progenitor cells (CD34
HPCs) and in vitro differentiated precursors: erythroblasts,
megakaryoblasts, monoblasts and myeloblasts (ERY, MKC,
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www.nature.com/cddisMONOandMYELO).WethereforeanalyzedthesemicroRNA
expression proﬁles together with the gene expression proﬁles
of the same populations and observed thatfor the most part of
themicroRNAsspeciﬁcallyupregulatedinonesingleprogeny,
an inverse correlation between microRNAs and downregu-
lated putative target expression levels occurs, that is, down-
regulated genes showed an enrichment for the conserved
putative targets of upregulated microRNA. Among these
microRNAs, hsa-miR-299-5p emerged as an interesting
candidate to show how the integrated analysis of microRNA
and mRNA expression data can help shedding light on the
regulatory mechanisms governing cell differentiation. In
particular, we used hsa-miR-299-5p to prove that the forced
expression of a single lineage-speciﬁc microRNA is able to
control the cell fate of CD34 HPCs grown in multilineage
culture conditions. Clonogenic and liquid culture differentia-
tion assays after gain- and loss-of-function experiments
revealed that indeed hsa-miR-299-5p regulates hematopoietic
progenitor fate modulating megakaryocytic-granulocytic
versus erythroid-monocytic development.
Results
Assessment of microRNA expression levels during
physiological myeloid differentiation. We compared the
expression proﬁle of 156 mature microRNAs obtained by
quantitative real-time PCR of each lineage precursor (ERY,
MKC, MYELO and MONO) with those of CD34 HPCs as
described in Materials and Methods section.
We selected those microRNAs whose expression was up-
or downregulated with a fold change greater than four in at
least one of the four precursor populations when compared
with the CD34 HPCs. When organized according to their
expression patterns, 23 microRNAs resulted oppositely
regulated, showing an upregulation in at least one precursor
population and, concomitantly, a counter-regulation in at least
another one (Figure 1).
MicroRNAs and mRNA expression integrated
analysis. The integrated analysis of microRNAs and
mRNA expression levels has been based on the
assumption that increased or decreased expression of a
speciﬁc microRNA results in, at least partially, decreased or
increased expression of corresponding target mRNAs.
Therefore, we investigated the existence of any inverse
correlation between the up or downregulated expression of a
micro-RNA and its predicted targets.
Figure 1 MicroRNAs oppositely regulated during myeloid differentiation.
Twenty-three microRNAs (indicated with the preﬁx miR-) show either up- or
downregulation greater than four in at least one precursor population when
compared with the CD34 HPCs; 17 showed a signiﬁcant increased expression with
an RQ higher than four, 15 a signiﬁcant decreased expression with an RQ lower
than  4 and concomitantly a counter-regulation in at least one other precursor cell
context. TaqMan real-time PCR reactions were carried out using the TaqMan
MicroRNA Assays Human Panel Early Access Kit. Delta-delta-CTs and RQs were
calculatedfor each detectorusing the CD34 HPC sample as the calibrator and hsa-
miR-let-7a as the endogenous control
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Cell Death and DiseaseWe compared microRNA and mRNA expression patterns
(i) focusing on 17 microRNAs out of the 23 described above,
which showed a signiﬁcant increased expression (relative
quantity, RQ, higher than four), and on the 15 microRNAs that
showed a signiﬁcant decreased expression (RQ lower than
 4) in at least one precursor population and (ii) verifying if
their ‘highly conserved,’ ‘conserved’ or ‘human only’ predicted
target transcripts are enriched in counter-regulated genes
(P-value of a hypergeometric test, see Materials and Methods
section). The 15 downregulated microRNAs showed very few
signiﬁcant P-values (Supplementary Figure S1A–B), but a
major part of the 17 upregulated microRNAs showed
signiﬁcant P-values when comparing each precursor with
the CD34 HPCs (i.e., along with differentiation, 11 out of 17
were signiﬁcant for at least one type of target), whereas a
minor part were signiﬁcant if compared with the other
precursor populations (i.e., along with speciﬁcity, 6 out of 17
were signiﬁcant) (Figure 2a and b).
For each microRNA, the analysis was performed
considering in separated tests the putative target mRNAs
with different levels of conservation, according to TargetScan
predictions: ‘human only’ targets, ‘conserved’ targets and
‘highly conserved’ targets were evaluated. The latter are
supposed to be more reliable targets of a speciﬁc microRNA;
nevertheless, human exclusive target genes may have a
pertinent role in speciﬁc biological processes. No relevant
Figure 2 MicroRNA–mRNA expression-integrated analysis. MicroRNAs and target mRNAs expression patterns were analyzed for the 17 upregulated microRNAs in one
speciﬁcprecursorcellcontext.Ahypergeometrictestwasusedtotesttheenrichmentindownregulatedtranscriptsamongtheirpredictedtargets:theanalyseswereperformed
considering in separated tests the putative target mRNAs with different levels of conservation (‘highly conserved,’ ‘conserved’ or ‘human only’ putative targets). Inverse
logarithm of the obtained P-values is plotted as a bar plot and the reference precursor cell type for each microRNA is speciﬁed in the bar plot labels. A hypergeometric test
resultwasconsideredsigniﬁcantiftheP-valuewasequaltoorlowerthan0.05.(a)P-valuesforthecomparisonsbetweenprecursorcellsandCD34HPCs;(b)P-valuesforthe
comparisons of each precursor cell context with the others
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Cell Death and Diseasewidespread differences emerged between ‘highly conserved,’
‘conserved’ and ‘human only’ targets.
Hsa-miR-299-5pmicroRNA,foundupregulatedinMKCand
downregulated in ERY, MYELO and MONO, showed a
signiﬁcant inverse correlation pattern (Figure 2a and b). We
chose this one as an exemplar microRNA to disclose the
potential biological bearing of this kind of analytical approach.
The differential expression of hsa-miR-299-5p supports
a role in CD34 HPC fate speciﬁcation. We veriﬁed the
expression levels of hsa-miR-299-5p microRNA in an
independent set of human progenitors and CD34 HPC
samples using TaqMan real-time PCR individual assay and
no signiﬁcant discrepancies were observed when compared
with the results obtained with TaqMan microRNA Assays
Human Panel Early Access Kit (Foster City, CA, USA)
(Supplementary Figure S2).
To assess the hsa-miR-299-5p expression pattern through-
out the studied myeloid differentiation pathways, a time
course evaluation of hsa-miR-299-5p expression was moni-
tored at 6, 9, 12 and 15 days of in vitro MKC, ERY, MYELO or
MONO differentiations of the same cord blood CD34 HPCs by
means of TaqMan real-time PCR; cytoﬂuorimetric analyses,
and monitoring of CD235a, CD41a, CD14 and CD66b
expression was performed alongside (see Materials and
Methods section). The hsa-miR-299-5p expression increased
quickly during MKC differentiation along with the appearance
and the increase of surface antigen CD41a. On the other
hand, the hsa-miR-299-5p microRNA showed no increase
during ERY differentiation induction, in MYELO or MONO
conditions, even if differentiation markers resulted induced
(Supplementary Figure S3a-b). We can therefore consider
hsa-miR-299-5p as a microRNA possibly involved in MKC
differentiation.
Hsa-miR-299-5p changes the balance of
commitment. Hsa-miR-299-5p was further analyzed to
determine whether the forced expression of a single
lineage-enriched micro-RNA could control the cell fate of
CD34 HPCs grown in multilineage culture conditions.
Clonogenic assays and liquid culture differentiation allowed
us to quantitate the proportion of megakaryocytic, erythroid,
monocytic and granulocytic cells and to estimate if the
perturbation of one micro-RNA expression can change the
balance of the following commitment. Transient transfection
of hsa-miR-299-5p precursor molecule was performed
through a single nucleoporation with the Amaxa Biosystem
(Cologne, Germany) Nucleofector device into cord blood CD34
HPCs. The result was a consistent and rapid upregulation of the
mature microRNA that was conﬁrmed by TaqMan real-time
PCR at different time points during in vitro culture of each cord
blood sample (Figure 3a). MicroRNA forced expression
biological effects were ﬁrst examined by evaluating the ex-
pression of unilineage differentiation surface markers: CD235a
that ﬁrst appears at the basophilic normoblast stage of erythroid
differentiation,
22 CD41a as an indicator of megakaryocytic
commitment,
23 CD14 distinguishing monocytic differentiation
24
while CD66b
25 reﬂects granulocytic cell fate. Hsa-miR-299-5p
overexpression reduced the percentage of CD235a-positive
cells (Figure 3b) and resulted in a decrease of erythroid burst-
forming unit (BFU-E) colonies in methylcellulose clonogenic
assays (Figure 3c). It also diminished the number of
erythrocytes in May Grunwald-Giemsa-stained cytospin prepa-
rations after 14 days of culture (Figure 4c and d). Besides, we
observed an increase in CD41a expression, of megakaryocytic
colonies in collagen-based assays (Figure 3b–d) and also of
MKC forms with their characteristic polynucleated elements in
morphologies (Figure 4c and d). Moreover, we reported
modiﬁcations in the expression of granulocyte and monocyte
markers and in the relative abundance of grown colonies:
the common trend consisted in an increase of the granu-
locytic tracts and in a drop of monocytic ones (Figures 3b,c
and 4c and d).
To complete these miR-299-5p forced expression studies,
we turned to a loss-of-function method. CD34 HPCs were
isolated and cultured for 72h in the presence of thrombo-
poietin (TPO) to assure the upregulation of the mature hsa-
miR-299-5p expression (Figure 5a). Then, we assayed them
for colony formation in methylcellulose and collagen in the
presence or absence of a 299-5p anti-miRNA inhibitor (see
Materials and Methods section). Hsa-miR-299-5p anti-miR
miRNA inhibitor (anti-299-5p) but not the anti-miR-negative
control 1 (anti-NC1) fully knocked down miR299-5p expres-
sion after 24h (Figure 5b). Treated samples with anti-299-5p
showed a decrease in CFU-Mk and colony-forming units
granulocyte (CFU-G) colonies, compared with anti-NC1
(Figure 5c and d), and a proportional increase in BFU-E
(Figure 5c).
Tocorroborate theseobservations, 24hafter hsa-miR-299-
5p forced expression, we evaluated some hematopoietic
differentiation markers by means of TaqMan real-time PCR
and measured a decrease in the erythroid-speciﬁc messen-
gers (Rh-associated glycoprotein, Rhag; hemoglobin alpha 1,
Hba1 and Kruppel-like factor 1, Klf-1) and an increase in the
Figure 3 Pre-miR miRNA Precursor Molecule transfections. (a) TaqMan real-time PCR of mature hsa-miR-299-5p expression after single transient transfection of its
precursor molecule through the Amaxa Nucleofector device. Hsa-miR-299-5p expression was monitored at different time points during in vitro culture using the nucleofection
solution-treated sample (nuc) as calibrator and RNU6b as endogenous control. (b) Cytoﬂuorimetric evaluation of the differentiation surface markers’ expression: CD235a for
erythroid differentiation, CD41a as indicator of megakaryocytic commitment, CD14 distinguishing monocytic differentiation and CD66b reﬂecting granulocytic cell fate. The
surface markers’ expression was checked after seven days of culture and each bar represents the fold change of the percentage of positivity normalized onto the pre-miR
miRNA precursor molecule-negative control # 1 (NC1)-treated sample. Asterisk indicates a t-test P-value p0.001. (c) Colony-forming capacity of HPCs transfected with pre-
miR miRNA precursor molecule(299-5p), when compared with Pre-miR miRNA Precursor molecule-negative control # 1 (NC1)-transfected cells andwith cells electroporated
with the nucleofection solution only (nuc). Mean±S.D. from four independent experiments. BFU-E: erythrocyte burst-forming unit; CFU-E: erythrocyte colony-forming unit;
GM-CFU: granulo-monocyte colony-forming unit; G-CFU: granulocyte colony-forming unit; M-CFU: monocyte colony-forming unit; GEMM-CFU: granulocyte-erythrocyte-
monocyte-macrophagecolony-formingunit.Asteriskindicatesa t-test P-valuep0.001.(d)Megakaryocyticcolony-forming capacityof HPCstransfectedwith pre-miRmiRNA
precursor molecule (299-5p), when compared with pre-miR miRNA precursor molecule-negative control # 1 (NC1)-transfected cells and cells electroporated with the
nucleofection solution only (nuc). Mean±S.D. from four independent experiments. Asterisk indicates a t-test P-value p0.001
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Cell Death and Diseasegranulocytic markers myeloperoxidase (Mpo) and elastase 2
(Ela2) together with the megakaryocytic-determining factor
friend leukemia virus integration 1 (Fli1) (Figure 6).
Discussion
Hematopoiesis involves a series of hierarchically organized
events that proceed throughout cell speciﬁcation and end
with cell differentiation. Commitment needs the transcription
factors’ effort, which, together with microRNAs, pivots cell
fate speciﬁcation, answering to promiscuous patterns of
gene expression by turning on lineage-speciﬁc genes and
repressing alternate lineage transcripts.
1 Therefore,
microRNAs and mRNAs seem to cooperate to direct cell fate
hematopoietic decisions. To date, those studies that
addressed the process of human hematopoietic commit-
ment focused on one or two differentiation pathways and
on single or very few microRNAs
15–18,20,21,26–29 with-
out attempting to explore any extensive correlation
between mRNA and microRNA expression proﬁles in multiple
samples.
We decided, therefore, to proceed to analyze different
hematopoietic precursors simultaneously (ERY, MKC,
MYELO and MONO) with the leading hypothesis that
increased expression of a cell-context-enriched microRNA is
believed to result in at least partial decreased expression of
matching target mRNAs.
Given the limited number of samples, we excluded the
application of the GenMiRþþalgorithm
30 for the analysis of
our data set. Indeed, although being a Bayesian method
speciﬁcally proposed for reﬁning the prediction of miRNA
targets through the combination of paired miRNA and mRNA
expression proﬁles, GenMiRþþ cannot guarantee robust
results for small data sets.
Figure 4 Morphologic analysis after pre-miR miRNA precursor molecule transfections. May–Grunwald staining ( 20 magniﬁcation, 0.5 aperture objective lenses (Carl
Zeiss)) of cytospin preparations after 14 days of culture in a representative experiment. Morphology was evaluated with an Axioskop 40 microscope (Carl Zeiss, Oberkochen,
Germany). The camera was inserted within the microscope. No software was used to optimize the ﬁgure. Objective lenses  20 and  40. (a) and (b) Precursor molecule-
negative control # 1-treated cells. (c) and (d) Hsa-miR-299-5p pre-miR miRNA precursor molecule-treated cells
Figure 5 Anti-miRNA inhibitormoleculetransfections. (a) TaqManreal-time PCR evaluationof maturehsa-miR-299-5p microRNA expression after 24,72 and96h of cell
culture in the presence of TPO (100ng/ml). Data were obtained using as calibrator the RNA of the same sample extracted immediately after CD34 HPC puriﬁcation and
RNU6basendogenouscontrol.Cellswereelectroporatedwithhsa-miR-299-5pinhibitorafter3daysofculture.(b)TaqManreal-timePCRmaturehsa-miR-299-5pexpression
after single transient transfection of its inhibitor molecule, through single nucleoporation with the Amaxa Nucleofector device. Expression withdrawal was monitored after one
and ten days from nucleofection. Data were obtained using as calibrator the nucleofection solution-treated sample (nuc) and RNU6b as endogenous control. (c) Colony-
forming capacity of HPCs transfected with hsa-miR-299-5p Anti-miR miRNA inhibitor (anti-299-5p), compared with Anti-miR miRNA inhibitor-negative control #1 (anti-NC1)-
transfected cells and cells electroporated with the nucleofection solution only (nuc). Mean±S.D. from three independent experiments. Asterisk indicates a t-test
P-valuep0.001.BFU-E:erythrocyteburst-formingunit;CFU-E:erythrocytecolony-formingunit;GM-CFU:granulo-monocytecolony-formingunit;G-CFU:granulocytecolony-
forming unit; M-CFU: monocyte colony-forming unit; GEMM-CFU: granulocyte-erythrocyte-monocyte-macrophage colony-forming unit. (d) Megakaryocytic colony-forming
capacity of HPCs transfected with hsa-miR-299-5p Anti-miR miRNA Inhibitor (anti-299-5p), compared with anti-miR miRNA inhibitor-negative control #1
(anti-NC1)-transfected cells and cells electroporated with the nucleofection solution only (nuc). Mean±S.D. from three independent experiments. Asterisk indicates a t-test
P-valuep0.001
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Cell Death and DiseaseHypergeometric tests conﬁrmed that target transcripts of
many upregulated hematopoietic microRNAs are enriched in
speciﬁc downregulated genes. This test represents a useful
indication, able to suggest the biological relevance of a
speciﬁc microRNA in shaping from a common CD34þ
progenitora peculiarandspecialized hematopoieticprecursor
and interfering with the differentiation processes throughout
its target genes. Furthermore, this kind of approach returns
hints of a relationship statistically signiﬁcant and completely
regardless of the established and/or putative role of target
mRNAs in myelopoiesis.
To conﬁrm this postulation, we decided to provide further
insights into microRNA’s biological role by studying the
potential unbalancing effects of a single microRNA during
the commitment of human CD34þ hematopoietic stem/
progenitor cells. Many studies showed that the change in
the expression of a single microRNA can reinforce single
lineage differentiation pathway into already committed cells or
into progenitors grown in unilineage conditions.
15–17,19,31
Lu et al.
18 recently assessed a causal role of miR-150 in the
speciﬁcation of megakaryocyte versus erythrocyte, when
using a bilineage primary cell culture system, where human
bone marrow CD34þ hematopoietic progenitors were
cultured in the presence of TPO and erythropoietin (EPO)
concomitantly.Weaskedinsteadiftheectopicexpressionofa
single lineage-speciﬁcmicro-RNA couldcontrol the cell fate of
CD34þ progenitors grown in multilineage conditions. This
method, testing if perturbation of one micro-RNA expression
can change the balance of the following commitment, allowed
us to estimate the proportion of all the four myeloid
populations. We chose hsa-miR-299-5p, whose microRNA-
mRNA’s inverse correlation was signiﬁcant, particularly when
considering‘highlyconserved’putativetargets.Hsa-miR-299-
5p overexpression in CD34 HPCs resulted to inﬂuence the
hematopoietic commitment. Moderate but consistent inverse
consequences of overexpression and knockdown experi-
ments and coherence with gene expression proﬁling data let
us conclude that hsa-miR-299-5p exerts its action of support
to the megakaryocytic pathway by impairing mostly the
erythroid precursors and preventing the block of granulocytic
differentiation.
In summary, we tested the existence of a close relationship
between microRNA and mRNA expression proﬁles during
hematopoietic physiological commitment. We established
signiﬁcant inverse correlations between some speciﬁcally
upregulated microRNAs and their putative mRNAs target
levels. We chose one micro-RNA from this selection and
veriﬁed its role in CD34 HPC commitment.
Materials and Methods
CD34þ Hematopoietic progenitor cells (CD34 HPCs)
puriﬁcation and liquid suspension cultures. Human CD34 HPC
cells were puriﬁed from umbilical cord blood samples, and collected anonymously
according to the institutional guidelines for discarded material and the Helsinki
declaration. Mononuclear cells were isolated using the EasySep Human Whole
Blood/Buffy Coat CD34-Positive Selection Kit (StemCell Technologies, Vancouver,
Canada) following the manufacturer’s instructions. Samples yielding a purity lower
than 95% were discarded.
MYELO and MONO were obtained from CD34 HPC cells as previously
described.
32 Brieﬂy, they were obtained by plating CD34 HPCs at a density of
0.5 10
6cells/ml in Iscove’s Modiﬁed Dulbecco’s Medium (IMDM) (GIBCO, Grand
Island, NY, USA) supplemented with 20% FBS (Bio-Whittaker, Walkersville, MD,
USA), 2mM L-glutamine, 100mg/ml streptomycin, 100U/ml penicillin, with the
addition of 50ng/ml stem cell factor (SCF), 50ng/ml FMS-like tyrosine kinase 3
ligand, 10ng/ml interleukin-6 and 10ng/ml interleukin-3 (all from R&D Systems,
Minneapolis, MN, USA). Cells were monitored by ﬂow cytometry for the expression
of CD14 and puriﬁed after 8 days of culture using the EasySep Human CD14-
Positive Selection kit (StemCell Technologies) that yielded a purity of 96.7%
(S.D.±2.4, n¼5).
Human MKCs were obtained, as formerly illustrated,
33 by plating CD34 HPC
progenitors at a density of 0.1 10
6cells/ml in IMDM (GIBCO) supplemented with
20%bovineserum albumin,insulinandtransferrin (BIT)serumsubstitute(StemCell
Technologies), 1mM L-glutamine, 100mg/ml streptomycin, 100U/ml penicillin, with
the additionof 100ng/ml humanrecombinant TPO (R&D Systems)every 3 days for
14 days. After 12–14 days of culture, MKC cells were puriﬁed using the EasySep
Do-It-Yourself Positive Selection kit (StemCell Technologies) and anti-CD41a
monoclonal antibody(BectonDickinson,SanJose,CA,USA)with a medianyield of
97.5% (S.D.±1.9, n¼5).
Human normal ERYs were obtained as previously explained
34 by plating CD34
HPCs at a density of 0.5 10
6cells/ml in IMDM supplemented with 20% BIT
(StemCell Technologies), 50ng/ml SCF and 4U/ml EPO (R&D Systems). Cells
were monitoredfor the expression of surfaceantigen CD235a every3 daysof liquid
culture and EPO was added. After 12–14 days of culture, cells were collected and
the purity assessed (92% CD235a-positive cells, S.D.±2.33, n¼5). Purity of
CD34 HPCs and precursor cell populations was also assessed with morphological
analysis, using MayGrunwald–Giemsa staining.
Figure 6 Evaluationof themyeloiddifferentiationmarkers’expressionbyquantitativereal-timePCR.Theﬁgureshowsthedecreaseoftheerythrocyteplasmamembrane
glycoprotein Rh-associated glycoprotein, Rhag; hemoglobin alpha 1, Hba1 and of the Beta-globin gene expression regulator, Kruppel-like factor 1(Klf1). Alongside, it shows
the increase in the granulocyticmarkers myeloperoxidase (Mpo) and elastase 2 (Ela2) together with the megakaryocytic-determining factor friend leukemiavirus integration 1
(Fli1). Nuclear factor (erythroid-derived 2), Nfe2, which is involved in the late differentiation phase of platelet assembly and release, as expected, was not signiﬁcantly
upregulated and neither were the monocytic markers interferon regulatory factor 8 (Irf8), Kruppel-like factor 4 (Klf4) and v-Maf musculoaponeurotic ﬁbrosarcoma oncogene
homolog B (Mafb). Delta-delta-CTs and RQs were calculated for each detector using as calibrator the nucleofection solution-treated sample (nuc) and glyceraldehyde-3-
phosphate dehydrogenase as endogenous control. Mean±S.D. from three independent experiments
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Cell Death and DiseaseMicroRNAexpression proﬁles. Total cellular RNA was extracted from ﬁve
CD34 HPCs, MYELO, MONO, MKC and ERY populations using the miRVana
miRNA Isolation kit (Life Technologies-Ambion, Austin, TX, USA) following the
manufacturer’s protocol. The quantity and purity/integrity of each sample was
quantiﬁed using Nanodrop 1000 (Thermo Fisher Scientiﬁc, Freemont, CA, USA)
and 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Five RNAs for
each cellular context were then pooled and checked again for purity and quantity.
Total RNAs were reverse transcribed and TaqMan PCR reactions were carried
out using the TaqMan MicroRNA Assays Human Panel Early Access Kit (Life
Technologies-Applied Biosystems, Foster City, CA, USA). PCR reactions were
performed using TaqMan Universal PCR Master Mix without AmpErase Uracil N-
glycosylase,bymeansoftheABIPRISM7900HTSequenceDetectionSystems(all
fromLifeTechnologies-AppliedBiosystems).Foreachpooledsample(CD34HPCs,
MYELO, MONO, MKC and ERY), we obtained data from the two 96-well plates
containingthemicroRNATaqManAssays(PlateAandPlateB).Weperformedthree
replicatesforeach of thetwoplates(Rep1, Rep2andRep3), andthereforethedata
set comprises a total of 30 ninety-six-well plates.
Statistical analyses were obtained using the 2-Delta-delta-Cycle Threshold
values(Delta-delta-CTs)method
35andtheThresholdwasdeterminedautomatically
by means of SDS Enterprise Edition software (Life Technologies-Applied
Biosystems). Delta-delta-CTs and RQ were calculated for each detector using
the CD34 HPCs sample as a calibrator and hsa-miR-let-7a as the endogenous
control (average CT for the ﬁve samples equal to 26.19; S.D.¼0.43).
All those microRNAs whose expression turned out to be undetermined or that
showed cycle threshold values higher than 34 in all populations, that is, ‘not
expressed’ in our data set, were ﬁltered out. MicroRNA expression data are
available in the gene expression omnibus (GEO) database with accession number
GSE17586 (http://www.ncbi.nih.gov/geo).
mRNAexpressionproﬁles. cDNAsynthesis,biotin-labeledtargetsynthesis,
HG-U133A GeneChip arrays hybridization, staining and scanning were performed
according to the GeneChip One-Cycle Target Labeling and Control Reagents protocol
supplied by the manufacturer (Affymetrix, Santa Clara, CA, USA).
Human myeloid data set. The data set of myeloid gene expression proﬁles
covered both CD34 HPCs and myeloid precursor cells (ERY, MYELO, MONO,
MKC). Raw data were obtained, processed and annotated as previously
described,
36 so as to remove probes with ambiguous matches to obtain gene
expression data with reliable biological annotations. Raw expression data ﬁles for
the human myeloid data set were previously published in the GEO database with
accession number GSE12803. The normalized data table obtained as already
described
36 is also provided as Supplementary material (Supplementary Table S1).
Median expression level is reported for each considered cell type that was used for
the integrated analysis of microRNA and mRNA expression proﬁles.
Integrated analysis of microRNA and mRNA expression
proﬁles. For each microRNA with increased expression in a speciﬁc precursor
cell type, putative targets were selected considering different conservation criteria,
as described below. Then, for each microRNA with increased expression in speciﬁc
precursor cell types, a hypergeometric test was used to verify whether putative
target transcripts are enriched in downregulated genes, or alternatively, if they are
enriched in genes with the lowest expression in that speciﬁc precursor cell context.
Conversely, the same approach was applied for downregulated microRNAs
evaluating the potential enrichment in putative target genes among upregulated
mRNAs. The genes were classiﬁed as downregulated or upregulated in a speciﬁc
precursor cell type, if they showed lower or higher median expression level,
respectively, in the speciﬁc precursor when compared with median expression level
in CD34 HPCs and if they showed the lowest or the highest expression in a speciﬁc
precursor cell context, when compared with the other precursors.
Hypergeometric test was implemented in R software and its result was
considered signiﬁcant if the P-value was equal to or lower than 0.05.
MicroRNA putative target selection. TARGETSCAN
(www.targetscan.com) version 4.1 was used to select putative target mRNAs for
each individual differentially expressed microRNA. We focused on putative targets
with different degrees of conservation across various organisms. The deﬁnition of
conserved and non-conserved putative mRNA targets is based on the identiﬁcation
of speciﬁc microRNA binding sites in each mRNA across different species,
according to TARGETSCAN 4.1 predictions. In particular, for each microRNA
considered, a list of ‘conserved target’ mRNAs was deﬁned by selecting mRNAs
with a speciﬁc microRNA binding site conserved in humans, mice, rats and dogs.
Then, a list of ‘human only targets’ was deﬁned by selecting transcripts with a
speciﬁc microRNA binding site that is present only in the human mRNA. Moreover,
for additional analyses, the lists of ‘highly conserved targets’ were deﬁned as
mRNAs with a speciﬁc binding site conserved both in mammals (humans, mice,
rats, dogs) and in chickens.
Pre-miR miRNA precursor molecule and Anti-miRNA inhibitor
transfections
Pre-miR miRNA precursor molecule transfections. After separation,
CD34HPCs were plated at the same conditions as previously described.
37 After 2
days of culture, they were transfected with the Amaxa Nucleofector Device, using
the Human CD34 Cell Nucleofection Kit, according to the manufacturer’s
instructions (Amaxa Biosystem), and 5mg of either the pre-miR miRNA precursor
molecule-negative control # 1 (NC1) or the hsa-miR-299-5p pre-miR miRNA
precursor molecule (Ambion, Austin, TX, USA) and pulsed with the program U-008.
Pre-miR negative control 1 is a random sequence pre-miR molecule that has
beenextensivelytestedinhumancelllinesandtissuesandvalidatedtonotproduce
identiﬁable effects on known miRNA function (http://www.ambion.com). To further
exclude nucleofection-aspeciﬁc effects, one sample was electroporated with the
nucleofection solution only (nuc).
Anti-miRNA inhibitor transfections. After separation, CD34 HPCs were
plated in IMDM (GIBCO), 20% BIT serum substitute (StemCell Technologies) and
TPO (100ng/ml) (R&D Systems).After 3 days of culture,they were transfectedwith
5mgofeithertheanti-NC1ortheanti-299-5p(Ambion)andpulsedwiththeprogram
U-008. Anti-miR negative control #1 is a random sequence anti-miR molecule that
has been extensively tested in human cell lines and tissues and validated to not
produce identiﬁable effects on known miRNA function (http://www.ambion.com). To
further exclude nucleofection-aspeciﬁc effects, one sample was electroporated with
the nucleofection solution only (nuc).
After 24h from either the hsa-miR-299-5p precursor or anti-miR nucleofections,
cells were plated following the manufacturer’s instructions in MethoCult GF H4434
complete methylcellulose medium for clonogenic assay (StemCell Technologies)
containingacocktailofrecombinanthumancytokines:SCF(50ng/ml),granulocyte-
macrophage colony-stimulating factor (10ng/ml), interleukin-3 (10ng/ml) and EPO
(3U/ml). After 14 days of culture at 371C in a humidiﬁed atmosphere with 5% CO2,
colonies were scored as BFU-Es, erythroid colony-forming units (CFU-E), CFU-G,
macrophage (CFU-M), granulocyte-macrophage and colony-forming units granu-
locyte/erythrocyte/macrophage/megakaryocyte.
After 24h from either the hsa-miR-299-5p precursor or anti-miR nucleofections,
cells were plated following the manufacturer’sinstructions in MegaCult-C (StemCell
Technologies) for megakaryocytic assay. CD34 HPCs were cultured at a density of
2.5 10
3/ml in a collagen-based medium and a 0.75ml cell suspension was
seeded per chamber of a double-chamber slide. This collagen-based system
contains a medium supplemented to a ﬁnal concentration with 1.1mg/ml collagen,
1% bovine serum albumin, 0.01mg/ml bovine pancreatic insulin, 0.2mg/ml human
iron-saturated transferrin and the human recombinant cytokines 50ng/ml TPO,
10ng/ml interleukin-3 and 10ng/ml interleukin-6. Chamber slides were incubated at
371Cfor12 daysandthenﬁxedfor20minin1:3methanol/acetone.Megakaryocyte
colonies were stained using a primary monoclonal anti-CD41 antibody and then
identiﬁed using an alkaline phosphatase detection system (all from StemCell
Technologies). Nuclei of all the cells regardless of lineage were counterstained with
Evans Blue. CD41-positive colonies were scored as CFU-Mk.
CD34HPCs were cultured and differentiation was monitored by morphological
analysisandbyﬂowcytometricanalysisofCD14,CD66b,CD235aandCD41asurface
antigen expression (Becton Dickinson), as previously described.
37
Real-time PCR. Total cellular RNA was extracted at different time points using
themiRVanamiRNAIsolationKit(Ambion)starting24hafternucleofectionofeither
the hsa-miR-299-5p precursor or the anti-miR molecule, and the expression of the
hsa-miR-299-5p mature microRNA was evaluated by means of the single real-time
PCR TaqMan MicroRNA Assay (Life Technologies-Applied Biosystems). Delta-
delta-CTs and RQ were calculated for each detector using as calibrator the nuc
sample and the TaqMan Control miRNA Assay RNU6b as endogenous control.
Hematopoietic lineage-speciﬁc messenger evaluation was assessed using
TaqMan Gene Expression Assays and TaqMan Universal PCR Master Mix (Life
Technologies-Applied Biosystems). Delta-delta-CTs and RQ were calculated for
each detector using as calibrator the nuc sample and glyceraldehyde-3-phosphate
dehydrogenase as endogenous control.
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